Sciele Pharma, Inc. And Plethora Solutions Holdings Announce That PSD502 Demonstrates Substantial Benefit in the Treatment of Premature Ejaculation
Published: Apr 28, 2009
ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc. a Shiongi Company, and Plethora Solutions Holdings PLC (“Plethora” – AME:PLE) today presented highly encouraging results from a European Phase III randomized, double-blind, placebo-controlled study of PSD502 for the treatment of premature ejaculation (PE). In this study, men treated with PSD502 five minutes before intercourse were able to delay ejaculation up to six times longer than those who used a placebo. Additionally, patients and their partners reported significant improvements in overall sexual satisfaction scores when using PSD502. The results were presented today at the American Urological Association Annual Meeting.